Leading Opinion Leader Decibio Highlights IsoPlexis and Functional Biomarkers as Future of Immune Medicine

The exploration of biomarkers in cancer immunotherapy has mostly focused on targeting tumor inflammation through PD-L1, TMB, etc., which are all either direct or indirect measurements of the presence or absence of immune cells in the tumor microenvironment. It has been suggested that simply measuring the presence of certain cells, proteins, or genes, is not enough to predict responders or non-responders to therapies. Functional biomarkers and analyses can provide more insight into the tumor-immune interaction by characterizing both the quality and type of immune response, in addition to providing clarity on the mechanisms behind disease progression and anti-tumor response.

A recent article from DeciBio discussed the rapid growth in the cancer immunotherapy biomarker field. IsoPlexis’ functional cellular proteomics was cited as a key extracellular phenotyping technologies. The article discussed challenges that researchers have encountered using traditional functional assays, such as difficult/complicated workflows and the predictive value of the data. With the recent innovations in the field of biomarkers, IsoPlexis’ functional proteomics is the new standard for biomarkers in cancer immunotherapy and has correlated to patient response in many studies.

IsoPlexis: The New Standard

As described in the article, legacy technologies are “limited in terms of automation, plex, and/or single-cell resolution, which are key parameters for enabling more advanced biomarker research and exploration. In recent years, however, the rise of single-cell, multiplex, and multi-omic analytical methods have been developed that enable more precise and powerful functional analyses.”

“Other companies, such as IsoPlexis (IsoLight)…have developed platforms and protocols for automated, live, single-cell analyses specifically for assessing cellular functionality, using extracellular signaling analysis. IsoPlexis, for example, has developed a proprietary metric (PSI—Polyfunctional Strength Index) based on single-cell cytokine secretions (>30 plex) across up to 1,000 single cells in parallel (per chip), and has shown the ability to use PSI as both a predictive biomarker as well as a tool for assessing the potency of cell therapies during development.”

With the newly launched CodePlex Secretome solution, obtaining highly multiplexed bulk cytokine metrics has never been easier. For the first time, the entire end-to-end highly-multiplexed ELISA workflow is fully automated with only five minutes of hands-on time. CodePlex Secretome only requires sample loading versus the multi-step process required on existing platforms and enables 20x faster data at the population level compared to existing protein multiplexing systems. With many researchers needing to run both single-cell and population cytokine assays, rather than purchasing multiple systems that require a lot of space and time to run, the IsoLight system serves as a proteomic hub that can automatically run both population and single-cell assays much faster and more efficiently than other systems currently available. IsoSpeak software suite is integrated into the award-winning, easy to use IsoLight system and automatically analyzes data from each chip and quickly produces various advanced visualizations that researchers can use to gain a full understanding of deep functional cellular insights. IsoSpeak’s advanced mapping tools are easily accessed via a push-button interface for accelerated same-day data analysis.

Be sure to download our full Product Catalog now to see our complete product line-up, including more information on our new products launching this month.

IsoPlexis IsoLight
Download the Product Catalog
Learn how the integrated IsoLight system can help you automate your entire workflow from sample prep to data analysis.
Share This Article
Subscribe to Follow the Data

Weekly email to keep you at the forefront of single-cell & multiplexed proteomics.